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Abstract
Introduction: Mechanically ventilated critically ill patients frequently develop ventilator-associated pneumonia
(VAP), a life-threatening complication. Proposed preventive measures against VAP include, but are not restricted to,
selective decontamination of the digestive tract (SDD), selective oropharyngeal decontamination (SOD) and the use
of probiotics. Probiotics are live bacteria that could have beneficial effects on the host by altering gastrointestinal
flora. Similar to SDD and SOD, a prescription of probiotics aims at the prevention of secondary colonization of the
upper and/or lower digestive tract.
Methods: We performed a literature review to describe the differences and similarities between SDD/SOD and
probiotic preventive strategies, focusing on (a) efficacy, (b) risks, and (c) the routing of these strategies.
Results: Reductions in the incidence of VAP have been achieved with SDD and SOD. Two large randomized
controlled trials even showed reduced mortality with these preventive strategies. Randomized controlled trials of
probiotic strategies also showed a reduction of the incidence of VAP, but trials were too small to draw firm
conclusions. Preventive strategies with antibiotics and probiotics may be limited due to the risk of emerging
resistance to the locally applied antibiotics and the risk of probiotic-related infections, respectively. The majority of
trials of SDD and SOD did not exhaustively address the issue of emerging resistance. Likewise, trials of probiotic
strategies did not adequately address the risk of colonization with probiotics and probiotic-related infection. In
studies of SDD and SOD the preventive strategy aimed at decontamination of the oral cavity, throat, stomach and
intestines, and the oral cavity and throat, respectively. In the vast majority of studies of probiotic therapy the
preventive strategy aimed at decontamination of the stomach and intestines.
Conclusions: Prophylactic use of antibiotics in critically ill patients is effective in reducing the incidence of VAP.
Probiotic strategies deserve consideration in future well-powered trials. Future studies are needed to determine if
preventive antibiotic and probiotic strategies are safe with regard to development of antibiotic resistance and
probiotic infections. It should be determined whether the efficacy of probiotics improves when these agents are
provided to the mouth and the intestines simultaneously.
Introduction
Ventilator-associated pneumonia (VAP) frequently com-
plicates the course of intubated and mechanically venti-
lated critically ill patients [1-3]. VAP is associated with a
decreased survival [4], although it is difficult to quantify
the exact attributable mortality [5,6]. Several approaches
for the prevention of VAP have been proposed, includ-
ing the use of ventilator bundles, specific practical mea-
sures such as hand hygiene in healthcare workers,
isolated interventions to prevent tracheal aspiration,
such as semi-recumbent positioning and subglottic
aspiration, and the use of silver-coated tubes [7-10].
Prevention of colonization of the upper and/or lower
digestive tract is another approach for the prevention of
VAP. This approach is built on the theory that the gas-
trointestinal flora changes with acute illness. In particu-
lar, it assumes that the normal flora disappears and is
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pathogenic microorganisms (PPM), followed by aspira-
tion of PPM, which could finally result in VAP.
There are roughly two approaches for the prevention
of colonization of the upper and/or lower digestive
tract. One strategy includes topical application of non-
absorbable antibiotics. Prevention of VAP has been
achieved in trials of selective decontamination of the
digestive tract (SDD) and trials of selective oropharyn-
geal decontamination (SOD). Another strategy uses topi-
cally applied probiotics, live bacteria that could alter
gastrointestinal flora. Recent trials of different probiotic
f o r m u l a ss u g g e s tt h i ss t r a t e g ya l s ot ob ee f f e c t i v ei nt h e
prevention of VAP.
This manuscript describes the rationale behind pro-
phylactic antibiotic and probiotic strategies in critically
ill patients. This is followed by a review dealing with the
beneficial effects, risks, and routing of prophylactic anti-
biotic or probiotic therapy. This manuscript does not
deal with oropharyngeal decontamination with chlorhex-
idine, which has the same principles as SOD. Isolated
interventions for the prevention of tracheal aspiration
are also not discussed.
Materials and methods
Data sources
Two methods were used to identify relevant manu-
scripts in the medical literature on SDD, SOD and pro-
biotic (or synbiotic) strategies. First, an electronic search
in the databases of Medline, Embase, the Cochrane
Library, the Cochrane Database of Systematic Reviews
and Sumsearch was conducted. Second, reference lists
of identified and selected manuscripts were reviewed for
additional relevant manuscripts. The search was
restricted to manuscripts published from 1980 until
now, and manuscripts written in English.
Keywords (MeSH and text word)
The following keywords were used to identity relevant
manuscripts: “critical care”, “intensive care”, “ventilator-
associated pneumonia”, “nosocomial pneumonia”,
“SDD”, “selective decontamination of the digestive
tract”, “selective gut decontamination”, “SOD”, selective
oropharyngeal decontamination”, “synbiotic”, “prebiotic”,
and “probiotic”.
Study selection
Titles and abstracts of identified manuscripts were
reviewed on: a) population (that is, adults in and type of
intensive care unit), b) intervention (that is, SDD, SOD
or probiotic therapy), c) outcome (VAP and mortality),
a n dd )t y p eo fs t u d y( r a n d o m i z e dc o n t r o l l e dt r i a lo r
other study types). In case of uncertainty the complete
manuscript was obtained and evaluated. We did not
restrict inclusion of manuscripts on methodological
quality or any other critically appraisal criteria other
than the criteria we formulated for data extraction. We
restricted inclusion of manuscripts of SDD to those stu-
dies that evaluated an SDD-regimen consisting of
administration of non-absorbable antibiotics in the
mouth and intestines, and a short course of systemic
antibiotics. We restricted inclusion of manuscripts of
SOD to those studies that evaluated an SOD-regimen
consisting of the administration of non-absorbable anti-
biotics solely in the mouth. We included all manuscripts
of probiotic therapy, (that is, administration of probio-
tics could be in the mouth, or the intestines, or both).
Finally, we restricted inclusion of manuscripts to those
that dealt with the general ICU population (that is, studies
in highly specific patient groups, such as liver transplant
patients, and studies of pediatric patients were ignored).
Data extraction
Manuscripts were criticized along three subjects: 1) Is
prophylactic use of antibiotics or probiotics preventing
VAP and reducing mortality? 2) What are the risks of
preventive use of antibiotics or probiotics in critically ill
patients? 3) What is the optimal route of administration
of preventive antibiotics or probiotics?
Results
The rationale for antibiotics or probiotics as preventive
measures against infections
Critical illness-associated infections
Critical illness-associated infections have been hypothe-
sized to be either primary endogenous or secondary
endogenous in their origin [11]. In this theory, primary
endogenous infections are caused by pathogens carried
in the oral cavity, throat, stomach and/or intestines of
patients on admission to the ICU. Secondary endogen-
ous infections are caused by pathogens thought to be
absent in the upper and lower digestive tract on admis-
sion, but to be acquired during the stay in ICU. A short
course of system antibiotics would prevent primary
endogenous infections. Secondary endogenous infections
would be banned if colonization could be prevented.
A second theory concerns the pathogenicity of micro-
organisms [11]. Pathogenicity can be expressed in the
“Intrinsic Pathogenicity Index” (IPI), the number of
patients infected by species X divided by the number of
patients carrying species X in the oropharynx, stomach
and/or intestines. Theoretically, the range of the IPI is 0
to 1: carriage of a microorganism with an IPI close to 0
w o u l ds e l d o mb ef o l l o w e db ya ni n f e c t i o n ;c a r r i a g eo fa
microorganism with an IPI close to 1 would almost
always be followed by an infection. Prevention of car-
riage with pathogens with an IPI close to 1 would bene-
fit critically ill patients, by preventing infections.
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intestinal flora have been hypothesized to increase colo-
nization with subsequent higher infection rates [12].
Disturbance or loss of the anaerobic flora would lead to
increased colonization and increased infection risk with
facultative aerobic bacteria. In this theory, it has been
s u g g e s t e dt h a tm o s to ft h ei n fections in ICU patients
are preceded by colonization of the stomach and intes-
tines with pathogenic micro-organisms.
SDD and SOD
SDD consists of selective eradication of PPM in the oral
cavity and decontamination of the stomach and intestines
by local administration of non-absorbable antibiotics, -
the first is reached by application of a paste, gel or
lozenge to the oral cavity, the second by administration
of a suspension through a nasogastric tube. Systemic pro-
phylaxis is provided by a short course of an intravenous
antimicrobial agent, to prevent respiratory infections
caused by commensal respiratory flora. Notably, the clas-
sical design of SDD also includes hand hygiene by health
care workers, and frequent surveillance cultures.
SOD consists of selective eradication of PPM in the
oral cavity by local administration of non-absorbable
antibiotics. SOD has been combined inconsistently with
systemic prophylaxis by a short course of an intravenous
antimicrobial agent.
Probiotics
The concept of selective decontamination with probio-
tics, with or without prebiotics, is at least in part based
on colonization resistance. Probiotics are live bacteria
that could have a beneficial effect on the host by alter-
ing gastrointestinal flora. Prebiotics are non-digestible
sugars that selectively stimulate the growth of certain
colonic bacteria. When administered in combination,
prebiotics could enhance the survival of probiotic strains
as well as stimulate the activity of the endogenous flora.
The combination of pre- and probiotics has been
termed “synbiotics”.
Administration of probiotics is not expected to eradi-
cate the PPM as antibiotics would do, but delaying the
time to colonization while the patients are intubated
and ventilated could be beneficial. Several probiotic and
synbiotic formulas are known and used. They usually
are a combination of lactic acid bacteria (including Lac-
tobacillus spp.) plus prebiotics, or a single-agent probio-
tic (Lactobacillus spp.).
Search results
The search recognized 64 manuscripts on SDD, 6
manuscripts on SOD and 9 manuscripts on probiotics.
Additional relevant manuscripts were not found in the
reference lists of identified and selected manuscripts.
Thirty manuscripts potentially answered one or more of
the above-mentioned questions.
Randomized controlled trials of prophylactic antibiotics
We identified 17 randomized controlled trials of SDD
[13-29], 5 randomized controlled trials of SOD [30-34],
and 8 randomized controlled trials of probiotics [35-42]
with VAP as one of the endpoints in critically ill
patients in general surgical and/or medical ICUs. Study
details and the main results of trials of SDD, SOD and
probiotics are presented in Tables 1, 2 and 3.
SDD appears to be an effective preventive strategy
against VAP (Table 1). Indeed, most studies showed
reductions in the incidence of VAP with SDD
[13-18,23,24,26-29]. Mortality, however, was affected in
only two studies [15,23]. Notably, SDD regimens used
were not always carefully described and concentrations
and dosing frequencies varied. Also, feeding regimens
and use of other antibiotics were described inconsis-
tently. In addition, patient populations varied widely. It
should also be noted that the diagnostic criteria for
VAP were at times rather loose; investigators may very
well have looked at the effect of SDD on bronchitis or
maybe even only respiratory tract colonization, rather
than VAP. Recent systematic reviews and meta-analyses,
including the majority of trials found by us, confirmed
S D Dt ob ea ne f f e c t i v es t r a t e g ya g a i n s tV A Ps h o w i n ga
reduced incidence of VAP [43-45].
SOD also appears to be an effective preventive strat-
egy against VAP (Table 2). Four out of five studies
showed reductions in the incidence of VAP with SOD
[30,31,33,34]. Like SDD, SOD had no effect on mortal-
ity. Similar to the randomized controlled trials of SDD,
studies of SOD were heterogeneous in many aspects. A
recent meta-analysis of trials of SOD showed this strat-
egy did not reduce the incidence of VAP [46].
Randomized controlled trials of prophylactic probiotics
Prophylactic use of probiotics also seems an effective
preventive strategy against VAP, albeit it to a lesser
extent (Table 3). Three out of eight studies showed a
significant reduction of VAP with probiotics [35,36,40].
Probiotics had no effect on mortality. Notably, two stu-
dies [41,42] were stopped prematurely after a study
reporting increased mortality in critically ill pancreatitis
patients receiving probiotics [47]. In most studies, pro-
biotics were administered solely to the stomach
[35,36,38,39,41,42], in one study [37] solely to the
mouth, and in one study to the stomach and the mouth
[40]. Studies of probiotics were also very heterogeneous.
Two recent meta-analyses of trials of probiotics in criti-
cally ill patients [48,49], of which one directly focused
on the effect of probiotics on VAP [48], drew different
conclusions. One meta-analysis showed administration
of probiotics to be associated with lower incidence of
VAP than standard care [48], the other meta-analysis
suggested that this prophylactic strategy conferred no
benefit [49].
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patients
One concern with prophylactic use of antibiotics is the
risk of the emergence of resistant bacteria [50,51]. Nota-
bly, colonization with resistant bacteria or an increase of
super-infections was reported inconsistently in the ran-
domized controlled trials of SDD or SOD. In fact, the
majority of trials of SDD/SOD did not exhaustively
address the issue of emerging resistance, as most were
not specifically designed for this outcome.
One study of SDD that specifically addressed the issue
of microbial resistance found no evidence for the selec-
tion of resistant bacteria in patients receiving prophylac-
tic antibiotics [29]. This was confirmed in another
report of long-term use of SDD [52]. Another large
study found that resistance rates of Gram-negative bac-
teria were actually higher in the control population than
in the SDD-treated population [53]. Interestingly, a
reduction in the incidence of multi-resistant Klebsiella
spp. was seen with prophylactic antibiotic use in three
other studies [54-56].
However, more recently it was shown that both SDD
and SOD markedly affect the bacterial ecology, with ris-
ing ceftazidime resistance prevalence rates in the
respiratory tract during intervention and a considerable
rebound effect of ceftazidime resistance in the intestinal
tract after discontinuation of SDD [57].
Because SDD and SOD are not active against resistant
Gram-positive bacteria, it may promote colonization
with bacteria such as Staphylococcus aureus and Entro-
coccus faecalis. SDD promotes colonization with resis-
tant Gram-positive bacteria [25,27,28,58,59]. Also, more
cases of Gram-positive bacteremia occurred in SDD-
treated patients [27]. It should be noted, though, that
these trials were all performed in countries with high
endemicity for Gram-positive bacteria. One study sug-
gests that the addition of oral vancomycin to SDD could
prevent colonization with resistant Gram-positive bac-
teria [60].
Risks of probiotic strategies in critically ill patients
One could expect that use of probiotics could cause
diarrhea in critically ill patients. Three of the eight
Table 1 Randomized controlled trials of selective decontamination of the digestive tract (SDD)
a,b
Author n VAP incidence (versus control) - % P-value Mortality (versus control) - % P-value
Kerver [13] 96 12 vs. 85% < 0.001 29 vs. 32% NS
Ledingham [14] 324 2 vs. 11% 0.006 24 vs. 24% NS
Ulrich [15] 100 15 vs. 50% < 0.001 31 vs. 54% < 0.02
Aerdts [16] 88 0 vs. 26% 0.0001 12 vs. 15% NS
Blair [17] 331 7 vs. 26% 0.002 15 vs. 19% NS
Hartenauer [18] 200 10 vs. 45% < 0.01 31 vs. 36% NS
Gastinne [19] 445 12 vs. 15% NS 34 vs. 30% NS
Cockerill [20] 150 4 vs. 5% NS 11 vs. 19% NS
Hammond [21] 322 7 vs. 6% NS 12 vs. 12% NS
Jacobs [22] 91 0 vs. 9% NS 39 vs. 54% NS
Rocha [23] 101 15 vs. 46% < 0.001 21 vs. 44% < 0.05
Winter [24] 183 3 vs. 18% < 0.05 36 vs. 43% NS
Ferrer [25] 80 18 vs. 24% NS 31 vs. 27% NS
Palomar [26] 83 17 vs. 50% 0.005 24 vs. 31% NS
Verwaest [27] 660 9 vs. 18% 0.026 18 vs. 17% NS
Sánchez-García [28] 271 11 vs. 29% < 0.001 39 vs. 47% NS
Krueger [29] 546 2 vs. 11% 0.007 20 vs. 29% NS
aTrials reporting incidence rates of pneumonia.
bAdministration of non-absorbable antibiotics in the mouth and the intestines, combined with a short course of
systemic antibiotics. VAP, ventilator-associated pneumonia; NS, not significant; -, no data available.
Table 2 Randomized controlled trials of selective oropharyngeal decontamination (SOD)
a,b
Author n VAP incidence (versus control) - % P-value Mortality (versus control) - % P-value
Rodriguiz-Roldan [30] 28 0 vs. 73% < 0.001 30 vs. 33% NS
Pugin [31] 52 16 vs. 78% < 0.0001 6 vs. 28% NS
Laggner [32] 67 3 vs. 12% NS 27 vs. 41% NS
Abele-Horn [33] 88 22 vs. 47% < 0.05 19 vs. 17% NS
Bergmans [34] 226 10 vs. 23% 0.04 29 vs. 43% NS
aTrials reporting incidence rates of pneumonia.
bAdministration of non-absorbable antibiotics solely in the mouth. VAP, ventilator-associated pneumonia; NS, not
significant; -, no data available.
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In these trials, the numbers of patients with diarrhea
was not different between patients who received probio-
tics and patients who did not.
Another concern with probiotics is colonization or
overgrowth with lactic acid bacteria. Notably, with pro-
biotics live bacteria are given to patients who could be
immunoparalyzed because of their critical disease. Such
patients could become colonized with probiotics, and
eventually develop probiotic-related disease. One recent
trial of probiotics in patients with pancreatitis was
stopped because of increased mortality [61]. In this
study, prophylaxis with probiotics was associated with
increased bacterial translocation and enterocyte damage
in patients with organ failure. Trials of probiotics
against VAP published so far did not sufficiently look at
this feared side-effect, although one report explicitly
mentioned that bacteremia with probiotics was not
found [42].
On a pre-specified subgroup analysis, Barraud et al.
found a reduction of the 28-day mortality among severe
sepsis patients treated with probiotics (odds ratio for
death 0.38, 95% confidence interval 0.16 to 0.93) [42]. In
contrast, probiotics were associated with a higher mor-
tality rate in non-severe sepsis patients (odds ratio for
death 3.09, 95% confidence interval 0.87 to 11.01). An
explanation for the reduction of the 28-day mortality
among severe sepsis patients may come from the fact
that these patients were sicker than non-severe sepsis
patients and a treatment effect may have been only
apparent in these more severely ill patients. This should
be confirmed by additional specific trials. But the inves-
tigators could not exclude a deleterious effect of probio-
tics on the less severely ill patients than those included
in the severe sepsis subgroup, although it was not linked
to probiotic-related disease, in particular infections.
Route of administration of prophylactic agents
With SDD, non-absorbable antibiotics are administered
in the mouth and intestines (and systemically, for the
first few days after admission to the ICU); as such it
should selectively eradicate of PPM in the oral cavity,
throat, stomach and the intestines (Figure 1). With
SOD, non-absorbable antibiotics are only administered
in the mouth, and should selectively eradicate PPM in
the oral cavity, and maybe throat, stomach and upper
intestines, if (parts of the) non-absorbable antibiotics are
swallowed. In only one study, probiotics were simulta-
neously administered in the mouth and the intestines
[40]. Probiotics were administered solely to the stomach
in the majority of the studies [35,36,38,39,41,42].
Discussion
One conclusion that can be drawn from the retrieved
randomized controlled trials of SDD in critically ill
patients is that this strategy is an effective measure
against VAP. Indeed, a vast majority of studies of SDD
showed reduction of VAP rates with this strategy. SOD
also seems an effective strategy against VAP. Notably,
SDD and SOD were found equally efficient strategies
with respect to prevention of mortality in critically ill
patients. The preventive effects against VAP of probio-
tics are less certain. Additional studies are needed to
confirm whether this strategy protects against VAP or
not.
Although not all trials of SDD showed a beneficial
effect, meta-analyses strongly suggested this prophylactic
strategy to be a very effective measure against VAP
[43-45]. Unfortunately, most studies of SDD were all too
small to show any effect on mortality. Two recent well-
powered randomized controlled trials of SDD, however,
showed reduction of mortality of critically ill patients
[53,62]. While these two trials did not report on reduc-
tions of VAP, it is suggestive that SDD lowered the inci-
dence of this important complication. Interestingly,
while the meta-analyses of trials of SOD showed no
reduction of VAP [46], one of the two recently per-
formed above mentioned trials showed also SOD to
reduce mortality of critically ill patients [62].
While only four trials of probiotics showed benefits in
critically ill patients, a recent meta-analysis suggested
Table 3 Randomized controlled trials of probiotic therapy
a
Author n VAP incidence (versus control) - % P-value Mortality (versus control) - % P-value
Kotzampassi
b [35] 134 54 vs. 80% 0.03 14 vs. 30% NS
Spindler-Vesel
b [36] 113 15 vs. 39% 0.03 8 vs. 6% NS
Forestier
c [37] 236 24 vs. 23% NS - -
Klarin
b [38] 50 4 vs. 14% NS 22 vs. 19% NS
Knight
b [39] 259 9 vs. 13% NS 27 vs. 33% NS
Morrow
d [40] 146 19 vs. 40% 0.007 18 vs. 21% NS
Oudhuis
b,e [41] 348 15 vs. 21% NS 26 vs. 26% NS
Barraud
b [42] 167 26 vs. 19% NS 25 vs. 24% NS
aTrials reporting incidence rates of pneumonia.
bAdministration of probiotics in the intestines.
cAdministration probiotics in the mouth.
dAdministration probiotics
in the mouth and in the intestines.
eProbiotic therapy was compared with selective decontamination of the digestive tract. VAP, ventilator-associated pneumonia;
NS, not significant; -, no data available.
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against VAP [48]. By contrast, one other meta-analysis
of probiotics did not show benefits in critically ill
patients [49]. Of note, after the publication of these two
meta-analyses, three trials of probiotics have been pub-
lished, two of them showed reduced incidences of VAP
with probiotic therapy [40-42]. The differences between
the two meta-analyses could be explained in different
w a y s .F i r s t ,o n em e t a - a n a l y s i sa l s oi n c l u d e dt r i a l so f
post-operative patients who are often admitted to the
I C Uf o rt o os h o r tat i m et od e v e l o pV A P[ 4 9 ] .S e c o n d ,
this meta-analysis did not include one important trial
that showed reduced rates of VAP with probiotics [35].
Considering the rationale for antibiotics or probiotics
as a preventive strategy against VAP, several remarks
must be made. The suggestion that critical illness-asso-
ciated infections are preceded by colonization of the
digestive tract with PPM has never been adequately pro-
ven, let alone whether there is causality between coloni-
zation and infection. Furthermore, it is important to
realize that the concept of colonization resistance has
been demonstrated only in gnotobiotic mice (mice in
Figure 1 Route of administration of prophylactic agents. (A) no prophylaxis; (B) the concept of SDD, with the application of non-absorbable
antibiotics in mouth and intestines; (C) the concept of SOD, with the application of non-absorbable antibiotics solely in the mouth (note that
agents applied in the mouth could get into the stomach); (D) application of probiotics as in most trials in critically ill patients.
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microorganisms are present), and its relevance has never
been documented in critically ill patients. Also, none of
the beneficial effects of probiotics with respect to colo-
nization prevention have been unequivocally demon-
strated in critically ill patients. Further remarks include
the fact that there are no studies that support the claim
that a short course of systemic antibiotics prevents pri-
mary endogenous infections. Finally, while in the classi-
cal design of SDD it was claimed that secondary
endogenous infections arise mostly from other patients
via the hands of caregivers (necessitating the need for
hand hygiene), this has never been supported by studies.
Also, it is uncertain whether frequent surveillance cul-
tures are needed to monitor the effectiveness of
decontamination.
What should be noted is that almost all publications
of trials of prophylactic antibiotics or probiotics lack a
discussion on standard preventive measures against
VAP. Such measures could include early weaning from
mechanical ventilation, hand hygiene, aspiration precau-
tions, and prevention of contamination, at times sum-
marized with the acronym “WHAP” [63]. In a single-
centre uncontrolled study it was demonstrated that an
educational initiative on WHAP, directed at respiratory
care practitioners and ICU nurses, was associated with
decreases in VAP incidence rates of up to 61% [63]. Of
course we should be careful in accepting results from
single-centre uncontrolled studies with non-specific cri-
teria for diagnosing VAP. However, it is suggestive that
one problem with the interpretation of the reviewed
trials of SDD, SOD and probiotics is that it is uncertain
whether caregivers complied with other prevention
strategies.
Although every literature review aims to find all stu-
dies addressing the question of the review, finding all
studies is not always possible. It has been shown that
those studies with significant results are easier to find
than those without significant results. Also, studies with
“positive” results are easier published than those with
“negative” results. Over-representation of studies with
significant results and “positive” studies in reviews may
cause bias toward a positive result. We cannot exclude
this to be the case in our review of antibiotics or pro-
biotics against VAP.
It is yet unclear whether probiotics offer their benefits
merely by preventing the colonization with PPM [64]. In
one randomized controlled trial a decrease in the inci-
dence of VAP was noted in patients receiving probiotics
despite the fact that their colonization rates were left
unaffected [39]. Another study showed that the adminis-
tration of live Lactobacillus as opposed to killed Lacto-
bacillus for the prevention of postoperative infections
did not add any effect [65]. The mechanism of action of
probiotics could be immunomodulatory more than non-
immunologic (that is, by preventing colonization with
PPM).
Should we use SDD or SOD?
One recently published trial evaluated the effectiveness
of SDD and SOD in a crossover study using cluster ran-
domization in 13 ICUs in The Netherlands [62]. Mortal-
ity was the primary endpoint (while VAP was not an
endpoint and not recorded). A total of 5,939 patients
were enrolled in this trial: 1,990 assigned to standard
care, 2,045 to SDD and 1,904 to SOD. Odds ratios for
death in the SDD and SOD groups, as compared with
the group of patients that received standard care, were
0.83, 95% confidence interval 0.72 to 0.97, and 0.86, 95%
confidence interval 0.74 to 0.99, respectively. This study
definitely supports the use of prophylactic antibiotics in
critically ill patients. This study, however, also leaves us
with a practical problem: Should we choose SDD or
SOD? It is not realistic to consider a new trial that com-
pares the effectiveness of SDD with SOD. Since there
w a so n l yas m a l ld i f f e r e n c ei ne ffectiveness in this last
trial, a new trial should include 10s of thousands of
patients to show superiority of SDD over SOD, or vice
versa.
Of course, one could (and should) consider the costs
of each strategy: $12 for SDD and $1 for SOD [62]. And
there is one other important issue that should be taken
into consideration: SDD and SOD may differ in their
risk of inducing antimicrobial resistance. Whether SDD
or SOD are favorable with regard to development of
antibiotic resistance is yet unknown. At present, a multi-
center cross-over comparison study of SDD and SOD in
ICU settings using either SDD or SOD for standard care
is running in The Netherlands. Results from clinical and
surveillance cultures will be used to assess development
of antibiotic resistance in different pathogens.
Should we use antibiotics or probiotics?
Prophylactic use may induce antimicrobial resistance.
M a n yt r i a l so fS D D( a n dS O D )h a v eb e e np e r f o r m e di n
The Netherlands, a country with low endemicity of
resistant bacteria. Dutch settings, however, may not be
representative for other settings. Without doubt, addi-
tional research is mandatory to determine whether SDD
and SOD are safe strategies with respect to antimicro-
bial resistance in countries with higher endemicity of
resistant pathogens.
Since probiotics are live bacteria, patients could
become colonized and eventually develop probiotic-
related infection. The currently available trials of probio-
tic therapy did not exhaustively address this issue, as
they were not specifically designed for this outcome and
were far too underpowered for that. Reports on VAP,
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[65-67], as well as a recently stopped trial of probiotics
in pancreatitis patients because of increased mortality
with probiotic treatment [47] suggest this scenario to be
realistic [61].
It should be realized that studies of probiotics so far
used different (combinations of) strains of live bacteria,
sometimes combined with prebiotics. Each strain of pro-
biotics may have additional, unique properties and
actions towards specific targets. Present knowledge on
these properties and actions, in particular in critically ill
patients, is insufficient.
Furthermore, there is a need for further clarifications
regarding doses, schedules and timing of probiotics for
prevention of VAP and colonization, as to-date a great
variability exists in the literature. Indeed, what should
be noted is that in most trials probiotics were solely
administered in the stomach. In only one trial the
investigators applied probiotics simultaneously to the
mouth and the intestines [40]. Interestingly, this trial
showed the largest beneficial effect of probiotics. By
contrast, with SDD antibiotics are administered in the
mouth and intestines; with SOD antibiotics are admi-
nistered exclusively in the mouth. It remains to be
determined what route is superior for probiotics: both
in the mouth (for oral eradication of PPM) and in the
intestines (for intestinal eradication of PPM), or only
in the intestines.
Conclusions
SDD and SOD seem efficient preventive measures
against VAP. SDD and SOD are equally effective with
respect to the prevention of mortality. Future studies of
SDD and SOD should address the issue of emerging
resistance with increased antimicrobial pressure. Given
the increasing antimicrobial resistance, probiotics
deserve consideration in new trials. Such trials should
be well-powered, and investigators should carefully con-
sider where to administer the probiotics: in the mouth,
in the intestines, or both. Finally, studies of probiotics in
critically ill patients should have active surveillance for
probiotic-induced diseases.
Key messages
￿ SDD and SOD are efficient preventive measures
against VAP and equally efficient strategies with respect
to prevention of mortality in critically ill patients.
￿ The majority of trials of SDD/SOD did not exhaus-
tively address the issue of emerging resistance, as most
were not specifically designed for this outcome and
were far too underpowered for that; use of SDD/SOD
may be limited due to the risk of emerging resistance to
the locally applied antibiotics.
￿ Trials of probiotic therapy did not adequately
address the risk of colonization with probiotics and pro-
biotic-related infection.
￿ Probiotic therapy deserves consideration in future
trials.
￿ Trials of probiotic therapy should be well-powered,
and investigators should carefully consider where to
administer the probiotics.
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